Category - Markets

Markets

Leede Jones Gable starts Oncolytics Biotech at speculative buy; PT $8.50 (Canadian)

Leede Jones Gable launched coverage of Oncolytics Biotech (TSX:ONC) with a “speculative buy” rating and $8.50 (Canadian) price target. The stock closed at $3.07 on Dec. 15. Oncolytics is a cancer-focused virus-based...

December 16, 2020

Markets

Leede Jones Gable starts Medical Facilities at buy; PT $10.50 (Canadian)

Leede Jones Gable initiated coverage of Medical Facilities (TSX:DR) with a “buy” rating and price target of $10.50 (Canadian). The stock closed at $7.32 on Dec. 15. Medical Facilities owns a majority stake in several U...

December 16, 2020

Markets

Leede Jones Gable starts CareRx at buy; PT $6.50 (Canadian)

Leede Jones Gable initiated coverage of CareRx (TSX:CRRX) with a “buy” rating and one-year price target of $6.50 (Canadian). The stock was quoted at $3.75, up 26 cents, near mid-day on Dec. 15. CareRx, formerly known as...

December 15, 2020

Markets

Leede Jones Gable starts Sernova at speculative buy; PT $1 (Canadian)

Leede Jones Gable launched coverage of Sernova (TSXV:SVA) with a “speculative buy” rating and price target of $1.00 (Canadian). The stock was quoted at 44 cents in early trading on Dec. 15. “We are positive on the...

December 15, 2020

Markets

Mackie Research ups Medexus Pharma PT to $9 (Canadian) from $6.30

Mackie Research Capital raised its price target for Medexus Pharmaceuticals (TSXV:MDP; OTCQX:MEDXF) to $9 (Canadian) from $6.30, citing positive momentum in sales of the company’s key drugs. The stock closed at $6.11 on...

December 15, 2020

Markets

SVB Leerink ups TCR2 Therapeutics PT to $41 from $28

SVB Leerink raised its price target for TCR2 Therapeutics (NASDAQ:TCRR) to $41 from $28, citing positive interim data from the ongoing Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing...

December 15, 2020

Markets

Raymond James starts Protech Home Medical at OP; PT $2 (Canadian)

Raymond James initiated coverage of Protech Home Medical (PTQ-TSXV) with an “outperform” rating and price target of $2 (Canadian). The stock closed at $1.44 on Dec. 14. Protech provides clinical respiratory equipment...

December 15, 2020

Markets

BTIG starts Aerpio Pharma at buy: PT $4

BTIG launched coverage of Aerpio Pharmaceuticals (NASDAQ:ARPO) with a “buy” rating and $4 price target. The stock closed at $2 on Dec. 8. “Aerpio is marching forward with several clinical programs of its first-in-class...

December 9, 2020

Markets

Stifel starts Venus Concepts at hold; PT $2.50

Stifel initiated coverage of Venus Concepts (NASDAQ:VERO) with a “hold” rating and price target of $2.50, citing “more work to be done in improving ARTAS,” the company’s robotic hair restoration system. The stock closed...

December 9, 2020

Markets

HCW ups Curis PT to $9 from $5

H.C. Wainwright raised its price target for Curis (NASDAQ:CRIS) to $9 from $5 after the company announced preliminary data from an ongoing Phase 1 study evaluating monotherapy, CA-4948, in relapsed or refractory acute...

December 8, 2020

Category - Markets

Leede Jones Gable starts Oncolytics Biotech at speculative buy; PT $8.50 (Canadian)

Leede Jones Gable starts Medical Facilities at buy; PT $10.50 (Canadian)

Leede Jones Gable starts CareRx at buy; PT $6.50 (Canadian)

Leede Jones Gable starts Sernova at speculative buy; PT $1 (Canadian)

Mackie Research ups Medexus Pharma PT to $9 (Canadian) from $6.30

SVB Leerink ups TCR2 Therapeutics PT to $41 from $28

Raymond James starts Protech Home Medical at OP; PT $2 (Canadian)

BTIG starts Aerpio Pharma at buy: PT $4

Stifel starts Venus Concepts at hold; PT $2.50

HCW ups Curis PT to $9 from $5

General

More